摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(甲氧基甲基)吡咯烷 | 76946-27-5

中文名称
2-(甲氧基甲基)吡咯烷
中文别名
——
英文名称
2-methoxymethylpyrrolidine
英文别名
2-(Methoxymethyl)pyrrolidine
2-(甲氧基甲基)吡咯烷化学式
CAS
76946-27-5
化学式
C6H13NO
mdl
MFCD01249587
分子量
115.175
InChiKey
CHPRFKYDQRKRRK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    142 °C
  • 密度:
    0.894
  • 闪点:
    46 °C

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    8
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933990090
  • 储存条件:
    应存放在室温环境下,避光保存,并在惰性气氛中保持稳定。

SDS

SDS:78cc3518f8ed5b87c5baa00751f78edd
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-(Methoxymethyl)pyrrolidine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Methoxymethyl)pyrrolidine
CAS number: 76946-27-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13NO
Molecular weight: 115.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(甲氧基甲基)吡咯烷正丁基锂dicobalt octacarbonyl 作用下, 以 为溶剂, 25.0~220.0 ℃ 、5.47 MPa 条件下, 反应 76.0h, 生成 1-(3,3-Dimethyl-2-oxo-butyl)-6-methoxymethyl-piperidin-2-one
    参考文献:
    名称:
    通过金属催化的扩环-羰基化反应区域选择性合成哌啶酮。显着的钴和/或钌羰基催化的重排和环化反应
    摘要:
    由羰基钴催化的吡咯烷的羰基化导致哌啶酮的形成。在大多数情况下,该反应是区域特异性的,当羰基钌作为第二催化剂存在时,产物的产率会增加。双催化体系 [Co 2 (CO) 8 /Ru 3 (CO) 12 ] 可用于杂环氮酮 ((CH 2 ) n NCH 2 COR, n=4-7] 在 72- 93% 的产率。2,6-二甲基哌啶基酮的一种不寻常的金属催化环化反应以 86-94% 的产率提供了 5,6,7,8-四氢茚茚
    DOI:
    10.1021/ja00044a010
  • 作为产物:
    参考文献:
    名称:
    WILSON, S. R.;PRICE, M. F., SYNTH. COMMUN., 1982, 12, N 9, 657-663
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • IDO INHIBITORS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20160289171A1
    公开(公告)日:2016-10-06
    There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    已披露的化合物可调节或抑制吲哌酮胺2,3-二氧化酶(IDO)的酶活性,含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病,如癌症、病毒感染和/或炎症性疾病的方法。
  • 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
    申请人:Warner-Lambert Company LLC
    公开号:EP1593679A1
    公开(公告)日:2005-11-09
    The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    这项发明涉及3-或4-单取代酚衍生物,以及用于制备、制备中间体、含有和使用这些衍生物的过程。所述的3-或4-单取代酚衍生物是H3配体,在许多疾病、紊乱和状况中非常有用,特别是炎症性、过敏性和呼吸系统疾病、紊乱和状况。
  • [EN] CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION<br/>[FR] AGENTS D'ARN CONJUGUÉS À DES GLUCIDES ET LEUR PROCÉDÉ DE PRÉPARATION
    申请人:ALNYLAM PHARMACEUTICALS INC
    公开号:WO2014025805A1
    公开(公告)日:2014-02-13
    This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.
    这份披露涉及一种改进的碳水化合物结合物制备过程。该披露还涉及包含这些碳水化合物结合物的碳水化合物结合iRNA药剂,其具有改进的纯度,并且对于iRNA药剂的体内输送是有利的。
  • [EN] AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE<br/>[FR] INHIBITEURS DE L'AUTOTAXINE CONTENANT UN NOYAU À CYCLE BENZYLE-AMIDE CYCLIQUE HÉTÉROAROMATIQUE
    申请人:NOVARTIS AG
    公开号:WO2015008230A1
    公开(公告)日:2015-01-22
    The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    本发明涉及新型化合物,这些化合物是自体磷脂酶抑制剂,涉及它们的制备方法,含有它们的药物组合物和药物,以及它们在由自体磷脂酶介导的疾病和紊乱中的应用。
  • CHEMICAL COMPOUNDS
    申请人:Deng Jianghe
    公开号:US20090143372A1
    公开(公告)日:2009-06-04
    The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    这项发明涉及新型吲哚羧酰胺衍生物。具体而言,该发明涉及符合以下式I的化合物: 其中R1、R2、R3、U和V如下定义,并且其药学上可接受的盐。该发明的化合物是IKK2的抑制剂,可用于治疗与不当IKK2(也称为IKKβ)活性相关的疾病,如类风湿性关节炎、哮喘和慢性阻塞性肺病(COPD)。因此,该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制IKK2活性和治疗相关疾病的方法。
查看更多

同类化合物

(2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁 阿维巴坦中间体1 阿曲生坦中间体 阿曲生坦 间甲氧基苯乙腈 铂(2+)羟基乙酸酯-吡咯烷-3-胺(1:1:1) 钾2-氧代吡咯烷-1-磺酸酯 钠1-[(9E)-9-十八碳烯酰基氧基]-2,5-二氧代-3-吡咯烷磺酸酯 金刚烷-1-基(吡咯烷-1-基)甲酮 酸-1-吡咯烷-1,4-氨基-2-甲基-1,1,1-二甲基乙基酯,(2S,4R)- 酚丙氢吡咯 试剂3-Mercaptopropanyl-N-hydroxysuccinimideester 西他利酮 血红素酸 螺虫乙酯残留代谢物Mono-Hydroxy 萘吡坦